Answers are grounded in this paper and cite their sources.
Atopic dermatitis is a chronic, pruritic immune mediated inflammatory dermatosis characterized by a T helper 2 cell immune response.1 It has been treated with topical corticosteroids, oral immunosuppressants, and light phototherapy.2 However, dupilumab has been a breakthrough medication in treating atopic dermatitis. Dupilumab is a human monoclonal antibody that blocks interleukin 4 (IL-4) and interleukin 13 (IL-13) and has been shown to be safe and helpful in treating a variety of conditions.1 Blockade of IL-4 and IL-13 is effective in reducing the T helper 2 response, likely explaining the mechanism of action in treating atopic dermatitis.
No takes yet. Share an insight, caveat, or question.
Fonseca et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: